H
Hannah Barker
Researcher at Ohio State University
Publications - 3
Citations - 191
Hannah Barker is an academic researcher from Ohio State University. The author has contributed to research in topics: Ponatinib & Erdafitinib. The author has an hindex of 3, co-authored 3 publications receiving 62 citations.
Papers
More filters
Journal ArticleDOI
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook,Julie W. Reeser,Gabrielle Ernst,Hannah Barker,Max Wilberding,Gary Li,Hui-Zi Chen,Sameek Roychowdhury +7 more
TL;DR: The expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma are described.
Journal ArticleDOI
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Melanie A. Krook,Alexandria M. Lenyo,Max Wilberding,Hannah Barker,Mikayla Dantuono,Kelly M. Bailey,Hui-Zi Chen,Julie W. Reeser,Michele R. Wing,Jharna Miya,Eric Samorodnitsky,Amy M. Smith,Thuy Dao,Dorrelyn M. Martin,Kristen K. Ciombor,John L. Hays,Aharon G. Freud,Sameek Roychowdhury +17 more
TL;DR: Findings from a patient with FGFR2-altered metastatic cholangiocarcinoma who enrolled in a phase II clinical trial of the FGFR inhibitor, infigratinib, support the development of novel combination therapeutic strategies in addition to the next generation of FGFR inhibitors to overcome acquired resistance in patients.
Journal ArticleDOI
Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Melanie A. Krook,Hannah Barker,Hui-Zi Chen,Julie W. Reeser,Michele R. Wing,Dorrelyn Martin,Amy M. Smith,Thuy Dao,Russell Bonneville,Eric Samorodnitsky,Jharna Miya,Aharon G. Freud,J. Paul Monk,Steven K. Clinton,Sameek Roychowdhury +14 more
TL;DR: The KLK2-FGFR2 fusion represents a novel target for precision therapies and should be screened for in men with prostate cancer.